RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Nyfeler, Beat ^a   Chen, Yan ^a   Li, Xiaoyan ^a   Pinzon Ortiz, Maria ^a   Wang, Zuncai ^a   Reddy, Anupama ^a   Pradhan, Elina ^a   Das, Rita ^a   Lehár, Joseph ^a   Schlegel, Robert ^a   Finan, Peter M ^a   Cao, Z Alexander ^a   Murphy, Leon O ^a   Huang, Alan ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; VON HIPPEL LINDAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CARCINOGENESIS; CATALYSIS; CELL LINEAGE; CELL PROLIFERATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG SYNERGISM; HUMANS; IMIDAZOLES; QUINOLINES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 84869122157     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048548     Document Type: Article

References (25)

1. Guertin DA, Sabatini DM, (2007) Defining the Role of mTOR in Cancer. Cancer Cell 12: 9-22.
2. Shaw RJ, Cantley LC, (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430.
3. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, et al. (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15: 148-159.
4. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, et al. (2010) Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17: 249-261 S1535-6108(10)00039-5 [pii];10.1016/j.ccr.2010.01.021 [doi].
5. Wullschleger S, Loewith R, Hall MN, (2006) TOR signaling in growth and metabolism. Cell 124: 471-484 S0092-8674(06)00108-5 [pii];10.1016/j.cell.2006.01.016 [doi].
6. Dancey J, (2010) mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 7: 209-219 nrclinonc.2010.21 [pii];10.1038/nrclinonc.2010.21 [doi].
7. Garcia-Echeverria C, (2011) Blocking the mTOR pathway: A drug discovery perspective. Biochemical Society Transactions 39: 451-455.
8. Vilar E, Perez-Garcia J, Tabernero J, (2011) Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 10: 395-403 1535-7163.MCT-10-0905 [pii];10.1158/1535-7163.MCT-10-0905 [doi].
9. Yip CK, Murata K, Walz T, Sabatini DM, Kang SA, (2010) Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell 38: 768-774 S1097-2765(10)00379-5 [pii];10.1016/j.molcel.2010.05.017 [doi].
10. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, et al. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168 S1097-2765(06)00218-8 [pii];10.1016/j.molcel.2006.03.029 [doi].
11. Maira S-M, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics 7: 1851-1863.
12. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, et al. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9: 341-349 S1535-6108(06)00116-4 [pii];10.1016/j.ccr.2006.03.029 [doi].
13. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J, (2008) Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A 105: 17414-17419 0809136105 [pii];10.1073/pnas.0809136105 [doi].
14. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38 08-PLBI-RA-4959 [pii];10.1371/journal.pbio.1000038 [doi].
15. Garcia-Martinez JM, Moran J, Clarke RG, Gray A, Cosulich SC, et al. (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 421: 29-42 BJ20090489 [pii];10.1042/BJ20090489 [doi].
16. Nyfeler B, Bergman P, Triantafellow E, Wilson CJ, Zhu Y, et al. (2011) Relieving autophagy and 4EBP1 from rapamycin resistance. Mol Cell Biol MCB.05430-11 [pii];10.1128/MCB.05430-11 [doi].
17. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284: 8023-8032 M900301200 [pii];10.1074/jbc.M900301200 [doi].
18. Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, et al. (2009) Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 69: 6232-6240 0008-5472.CAN-09-0299 [pii];10.1158/0008-5472.CAN-09-0299 [doi].
19. Xu CX, Li Y, Yue P, Owonikoko TK, Ramalingam SS, et al. (2011) The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PLoS One 6: e20899 10.1371/journal.pone.0020899 [doi];PONE-D-11-05608 [pii].
20. Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, et al. (2012) mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma. Sci Transl Med scitranslmed.3003923 [pii];10.1126/scitranslmed.3003923 [doi].
21. Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, et al. (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 27: 659-666 nbt.1549 [pii];10.1038/nbt.1549 [doi].
22. Zimmermann GR, Lehar J, Keith CT, (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12: 34-42 S1359-6446(06)00469-7 [pii];10.1016/j.drudis.2006.11.008 [doi].
23. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, et al. (2009) Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A 106: 22299-22304 0905152106 [pii];10.1073/pnas.0905152106 [doi].
24. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356 nm.1890 [pii];10.1038/nm.1890 [doi].
25. Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, et al. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463: 501-506 nature08675 [pii];10.1038/nature08675 [doi].